Biopharma

Enabling biopharma to accelerate the production of innovative medicines to address complex diseases.

Over the last 20 years, next-generation sequencing (NGS) has become an indispensable tool for biopharma companies, contract research organisations (CROs) and contract development and manufacturing organisations (CDMOs), across the whole biopharma value chain, to support different applications.

However, there is a growing recognition that traditional "short-read" sequencing methods, which require amplification and fragmentation of DNA or RNA molecules, erase critically important information.

A new generation of sequencing technology

Nanopore sequencing from Oxford Nanopore Technologies overcomes such limitations and offers an innovative approach: direct sequencing of DNA or RNA fragments any length quickly and efficiently. This approach can be utilised across the whole drug discovery value chain, and the ultra-rich genetic data generated provides an important tool in the continuing drive to boost data-driven decision making, and in turn, improve the probability of success (PoS) of drug discovery and development programs.

Nanopore sequencing delivers:

  • Ultra-rich data — for comprehensive insights
  • Any read length — from short to ultra-long (>4 Mb)
  • PCR free — no amplification bias
  • Built-in methylation detection — no additional bisulfite sequencing runs required
  • Real-time analysis — immediate access to actionable results

Oxford Nanopore Technologies is already well established in many areas of life science research with >8,000 users worldwide across 120 countries. These users have published >8,200 publications in human genetics, cancer, plant, animal, and microbial biology.

Such research has served as a foundation for the development of solutions in many industries, including biopharma, which is a particularly active area of development in 2024.

The schematic below shows the current focus areas:

Find out more about solutions for cell and gene therapy

Next-generation sequencing (NGS) is now an essential tool across the drug development value chain; however, the requirement of traditional NGS technologies for nucleic acid fragmentation and amplification erases critical sample information. Nanopore sequencing from Oxford Nanopore Technologies overcomes these limitations to reveal the true biology of your samples.

Download brochure
Gene therapy brochure

Learn how nanopore sequencing works

Oxford Nanopore has developed a new generation of DNA/RNA sequencing technology. It is the only sequencing technology that offers real-time analysis (for rapid insights), in fully scalable formats, from pocket to population scale, that can analyse native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths.

Discover nanopore sequencing

A range of sequencing devices and flow cells allows great flexibility to tailor your throughput and application needs more precisely.

MinION devices card header

MinION

The only portable, real-time devices for DNA and RNA sequencing, giving complete control and creativity over when, where, and how often you sequence, regardless of application.

GridION device card header

GridION

Self-contained, easily deployable benchtop devices designed to run and analyse up to five MinION or Flongle Flow Cells. Simple, robust scalability for all your sequencing needs.

PromethION device card header

PromethION

High-coverage nanopore sequencing in formats ranging from modular, fully integrated devices, to high-throughput solutions. Each flow cell can deliver the lowest price per Gb for nanopore sequencing.